Skip to content

Foresite Capital Management V, LLC

Follow

13F filer, CIK 1792206, West Hollywood, CA

Foresite Capital Management V, LLC reported $289,147,716 across 9 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.

Accepted , ingested 13F-HR 0001104659-26-128380

Period
2026-09-30
Reported value
$289M
Holdings
9
Top 10 weight
100%
New
1
Sold out
1

Part of the filer group Foresite Capital Management VI LLC

How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • IRLA QUINCE THERAPEUTICS INC: 13G 652,039 shares, 6% of the class, 13G filed 2026-10-14, 0001104659-26-115859Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LTGOnew+3,562,984$59.5M
NRIXadded+193,742$4.59M
HIMSadded+145,600$4.34M
ODTXadded+16,497$367K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELexited-476,386-$6.69M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-128380, largest first. % of portfolio is the value over $289,147,716, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 692,550 shares; 2025Q1: 859,050 shares; 2025Q2: 1,004,050 shares; 2025Q3: 1,004,050 shares; 2025Q4: 1,004,050 shares; 2026Q1: 1,004,050 shares; 2026Q2: 1,079,050 shares; 2026Q3: 1,079,050 shares 1,079,050$76.5M26.45%0Timeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,562,984 shares 3,562,984$59.5M20.58%newTimeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,779,348 shares; 2025Q1: 5,779,348 shares; 2025Q2: 5,779,348 shares; 2025Q3: 5,779,348 shares; 2025Q4: 5,779,348 shares; 2026Q1: 5,896,995 shares; 2026Q2: 5,896,995 shares; 2026Q3: 5,896,995 shares 5,896,995$43.6M15.07%0Timeline
HIMSHIMS & HERS HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 939,860 shares; 2025Q1: 273,151 shares; 2025Q2: 273,151 shares; 2025Q3: 273,151 shares; 2025Q4: 273,151 shares; 2026Q1: 738,151 shares; 2026Q2: 738,151 shares; 2026Q3: 883,751 shares 883,751$26.3M9.11%+145,600Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 299,069 shares; 2025Q1: 299,069 shares; 2025Q2: 299,069 shares; 2025Q3: 299,069 shares; 2025Q4: 299,069 shares; 2026Q1: 374,069 shares; 2026Q2: 374,069 shares; 2026Q3: 374,069 shares 374,069$24.5M8.47%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 194,125 shares; 2026Q2: 664,142 shares; 2026Q3: 664,142 shares 664,142$21.1M7.29%0Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 713,105 shares; 2026Q3: 729,602 shares 729,602$16.2M5.61%+16,497Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 265,000 shares; 2026Q2: 265,000 shares; 2026Q3: 458,742 shares 458,742$10.9M3.76%+193,742Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,318,983 shares; 2026Q2: 1,318,983 shares; 2026Q3: 1,318,983 shares 1,318,983$10.6M3.67%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LYELLYELL IMMUNOPHARMA INC476,386$6.69Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-128380 base2026-11-16